De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection

Sci Transl Med. 2020 Aug 19;12(557):eaaz3738. doi: 10.1126/scitranslmed.aaz3738.


The adaptive immune system recognizes tumor antigens at an early stage to eradicate cancer cells. This process is accompanied by systemic proliferation of the tumor antigen-specific T lymphocytes. While detection of asymptomatic early-stage cancers is challenging due to small tumor size and limited somatic alterations, tracking peripheral T cell repertoire changes may provide an attractive solution to cancer diagnosis. Here, we developed a deep learning method called DeepCAT to enable de novo prediction of cancer-associated T cell receptors (TCRs). We validated DeepCAT using cancer-specific or non-cancer TCRs obtained from multiple major histocompatibility complex I (MHC-I) multimer-sorting experiments and demonstrated its prediction power for TCRs specific to cancer antigens. We blindly applied DeepCAT to distinguish over 250 patients with cancer from over 600 healthy individuals using blood TCR sequences and observed high prediction accuracy, with area under the curve (AUC) ≥ 0.95 for multiple early-stage cancers. This work sets the stage for using the peripheral blood TCR repertoire for noninvasive cancer detection.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm
  • Humans
  • Major Histocompatibility Complex
  • Neoplasms* / diagnosis
  • Neoplasms* / genetics
  • Receptors, Antigen, T-Cell* / genetics
  • T-Lymphocytes


  • Antigens, Neoplasm
  • Receptors, Antigen, T-Cell